News - Human Genome Sciences

Filter

Current filters:

Human Genome Sciences

Popular Filters

GlaxoSmithKline goes on attack over Human Genome bid

09-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) went into attack mode this morning, taking its unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceutical

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

GSK takeover target Human Genome sees 4th-qtr loss narrow

25-04-2012

Human Genome Sciences (Nasdaq: HGSI), the subject of a $2.59 billion hostile takeover bid from the UK's…

BenlystaBiotechnologyFinancialHuman Genome Sciences

Human Genome rejects unsolicited takeover bid from GlaxoSmithKline

20-04-2012

US drugmaker Human Genome Sciences (Nasdaq: HGSI) revealed yesterday that it has rejected an unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Ph III albiglutide data in type 2 diabetes supports move to filing, says GSK

03-04-2012

UK pharma giant GlaxoSmithKline plc (LSE: GSK) says that top-line results have been received from seven…

albiglutideDiabetesGlaxoSmithKlineHuman Genome SciencesPharmaceuticalResearch

Human Genome Sciences’ Benlysta sales disappoint

11-01-2012

US biotech firm Human Genome Sciences (Nasdaq: HGSI) president and chief executive Thomas Watkins yesterday…

BenlystaBiotechnologyFinancialHuman Genome SciencesMarkets & MarketingRare diseasesraxibacumab

Benlysta gaining bigger US market share

13-12-2011

Over half of surveyed US rheumatologists surveyed by Decision Resources unit BioTrends have initiated…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRare diseases

Systemic lupus erythematosus drug market to grow to $1.6 billion in 2018

10-11-2011

The global systemic lupus erythematosus (SLE) therapeutics market in the seven leading countries ( the…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineGlobalHuman Genome SciencesMarkets & MarketingPharmaceutical

Important decision for the biotech industry from UK Supreme Court

03-11-2011

The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports

18-10-2011

Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Human Genome Sciences names senior VP; Avanir appoints R&D chief

08-08-2011

USA-based Human Genome Sciences (Nasdaq: HSGI) says that Craig Parker has joined the company as senior…

Avanir PharmaceuticalsBiotechnologyHuman Genome SciencesManagementPharmaceutical

Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends

07-08-2011

Rheumatologists are maintaining enthusiasm for Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceutical

Back to top